Sisram Medical reports strong Q3 order momentum, double-digit revenue growth

Sisram Medical Ltd announced strong market momentum in new orders for the third quarter of 2025, primarily fueled by demand in China, South Korea, and Thailand. The company's flagship multi-modal platform, Alma Harmony, significantly contributed to this growth with a solid increase in system orders. This performance led to healthy double-digit year-on-year growth in the group's unaudited revenue for the quarter.

The group plans to continue its proactive market development by advancing the deployment of its Soprano family in the APAC region and expanding sales of Universkin by Alma in the U.S. market in the coming months. Additionally, Sisram Medical is progressing with commercial readiness for the upcoming DAXXIFY launch in Mainland China.

This announcement is based on a preliminary review of unaudited operational data and has not been reviewed or audited by the group's auditors. The company advises shareholders and potential investors to exercise caution, as the data does not represent the full financial picture.